Thrombosis in the Young: Effect of Atherosclerotic Risk Factors on the Risk of Myocardial Infarction Associated with Prothrombotic Factors

D S Siscovick; S M Schwartz; F R Rosendaal; B M Psaty

doi:10.1055/s-0038-1657493

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1997; 78(01): 007-012
DOI: 10.1055/s-0038-1657493

Thrombosis in the young

Schattauer GmbH Stuttgart

Thrombosis in the Young: Effect of Atherosclerotic Risk Factors on the Risk of Myocardial Infarction Associated with Prothrombotic Factors

D S Siscovick

Cardiovascular Health Research Unit, Departments of Medicine and Epidemiology, University of Washington, Seattle, WA, USA

,

S M Schwartz

Cardiovascular Health Research Unit, Departments of Medicine and Epidemiology, University of Washington, Seattle, WA, USA

,

F R Rosendaal

Cardiovascular Health Research Unit, Departments of Medicine and Epidemiology, University of Washington, Seattle, WA, USA

,

B M Psaty

Cardiovascular Health Research Unit, Departments of Medicine and Epidemiology, University of Washington, Seattle, WA, USA

› Author Affiliations

Abstract

PDF Download

PDF (1320 kb)

References

References
1 Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth WT, Ragunathan TE, Koepsell TD, Reitsma PH. Factor VLeiden (resistance to activatedproteinC) increases therisk of myocardial infarction in young women. In Press Blood. 1997
2 Davies MJ. Stability and instability: two faces of coronary atherosclerosis: The Paul Dudley White Lecture 1995. Circulation 1996; 94: 2013-2020
3 Ambrose JA, Tannenbaum MA, Alexopoulos D, Hjemdahl-Monsen GE, Leavy J, Weiss M, Borrico S, Gorlin R, Fuster V. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 1988; 12: 56-62
4 Little WC, Constantinescu M, Applegate RJ, Kutcher MA, Burrows MT, Kahl FR, Santamore WP. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease?. Circulation 1988; 78: 1157-1166
5 Uhl GS, Farrell PW. Myocardial infarction in young adults: risk factors and natural history. Am Heart J 1983; 105: 548-553
6 Zimmerman FH, Cameron A, Fisher LD, Ng G. Myocardial infarction in young adults: angiographic characterization, risk factors and prognosis (Coronary Artery Surgery Study Registry). J Am Coll Cardiol 1995; 26: 654-656
7 Sydney S, Petitti DB, Quesenberry CP, Klatsky AL, Ziel HK, Wolf S. Myocardial infarction in users of low-dose oral contraceptives. Obstet Gynecol 1996; 88: 939-944
8 Bergstrand R, Vedin A, Wilhelmsson C, Wallin J, Wedel H, Wilhelmsen L. Myocardial infarction among men below age 40. Brit Heart J 1978; 40: 783-788
9 Kanitz MG, Giovannucci SJ, Jones JS, Mott M. Myocardial infarction in young adults: risk factors and clinical features. J Emerg Med 1996; 14: 139-145
10 McKenna WJ, Chew CYC, Oakley CM. Myocardial infarction with normal coronary angiogram: possible mechanism of smoking risk in coronary artery disease. Br Heart J 1980; 43: 493-498
11 Stadel BV. Oral contraceptives and cardiovascular disease (first of two parts). N Engl J Med 1981; 305: 612-618
12 Sartwell PhE, Stolley P. Oral contraceptives and cardiovascular disease. Epidemiol Rev 1982; 4: 095-109
13 Wenger NK. Gender differences in coronary risk and risk factors. In: Prevention of Myocardial Infarction. Manson JE, Ridker PM, Gaziano JM, Hennekens CH. eds Oxford University Press; New York: 1996. pp 387-412
14 Rissanen Am, Nikkila EE. Role of family history in coronary heart disease at young age. In: Roskamm H. ed Myocardial infarction at young age. Heidelberg; Springer-Verlag: 1981
15 Dammerman M, Breslow JL. Genetic determinants of myocardial infarction. In: Prevention of Myocardial Infarction. Manson JE, Ridker PM, Gaziano JM, Hennekens CH. eds Oxford University Press; New York: 1996. PP 55-88
16 Orth-Gomer K, Mittleman MA, Schenk-Gustafsson K, Wamala SP, Eriksson M, Belkic K, Kirkeeide R, Svane B, Ryden L. Lipoprotein(a) as a determinant of coronary heart disease in young women. Circulation 1997; 95: 329-334
17 Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 1993; 270: 2195-2199
18 Mead TW, Brozovic M, Chakrabarti RR, Haines AP, Imeson JD, Mellows S, Miller GJ, North WRS, Stirling Y, Thompson SG. Haemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 533-537
19 Ridker PM, Hennekens CH, Cerskus A, Stampfer MJ. Plasma concentration of cross-linked fibrin degradation product (D-Dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation 1994; 90: 2236-2240
20 Ridker PM, Vaughan DE, Stampfer MJ. Endogenous tissue-type plasminogens activator and risk of myocardial infarction. Lancet 1993; 341: 1165-1168
21 Mead TW, Imeson J, Stirling Y. Effects of changes in smoking and other characteristics on clotting factors and the risk of ischaemic heart disease. Lancet 1988; 986-988
22 Mead TW. Fibrinogen in ischemic heart disease. Euro Heart J 1995; 16 (suppl A) 31-35 Hamsten A, Wiman B, de Fai, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-1563
23 Lee AJ, Flanagan A, Rumley A, Fowkes FGR, Lowe GDO. Relationship between alcohol intake and tissue plasminogen activator antigen and other haemostatic factors in the general population. Fibrinolysis 1995; 8: 49-54
24 Ridker PM, Vaughan DE. Potential antithrombic and fibrinolytic properties of the angiotensin converting enzyme inhibitors. J Thromb Thrombolysis 1995; 1: 251-257
25 Fugii S, Sobel BE. Direct effects of gemfibrozil on the fibrinolytic system: diminution of synthesis of plasminogen activator inhibitor type 1. Circulation 1992; 85: 1888-1893
26 Folsom AR, Qamhieh HT, Wing RR, Jeffery RW, Stinson VL, Kuller LH, Wu KK. Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatis factors in moderately overweight adults. Arterioscler Thromb 1993; 13: 162-169
27 Vague P, Juhan-Vague I, Aillaud MR, Badier C, Viard R, Alessi MC, COllecn D. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism 1986; 35: 250-253
28 Meilahn EN, Kuller LH, Mathews KA, Kiss JE. Hemostatic factors according to menopausal status and use of hormones replacement therapy. Ann Epidemiology 1992; 2: 445-455
29 Scarabin PY, Plu-Bureau G, Bara L, Bonithon-Kopp C, Guize L, Samama MM. Haemostatic variables and menopausal status: influence of hormone replacement therapy. Thrombosis and Haemostasis 1993; 70: 584-587
30 Laug WE. Ethyl alcohol enhances plasminogen activator secretion by endothelial cells. JAMA 1983; 250 (06) 772-776
31 Yarnell JW, Baker IA, Sweetnam PM, et al. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease: the Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation 1996; 83: 836-844
32 Ridker PM, Vaughan DE, Stampfer MJ, Sacks FM, Hennekens CH. A cross-sectional study of endogenous tissue plasminogen activator, total cholesterol, HDL cholesterol, and apolipoproteins A-I,A-II, and B-100. Arterioscler Thromb 1993; 13: 1587-1592
33 Yu Q, Safavi F, Roberts R, Marian AJ. A variant of b fibrinogen is a genetic risk factor for coronary artery disease and myocardial infarction. J Investig Med 1996; 44: 1540159
34 Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Miletich JP. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation 1997; 95: 59-62
35 Erikson P, Kallin B, van’t Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plas-minogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92: 1851-1855
36 Weiss EJ, Bray PF, Tayback M, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996; 334: 1090-1094
37 Carter AM, Ossei-Geming N, Grant PJ. Platelet glycoprotein Ilia PLA polymorphism in young men with myocardial infarction. Lancet 1996; 347: 485-486
38 Ridker PM, Hennekens CH, Schmitz C, Stampfer MJ, Lind paintner. PI^A1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet 1997; 349: 385-388
39 Newman PJ. Platelet alloantigens: cardiovascular as well as immunological risk factors?. Lancet 1997; 349: 370-371
40 Allaart CF, Poort SR, Rosendaal FR, Reitsma PH, Bertina RM, Briet E. Increased risk of venous thrombosis in carriers of protein C deficiency defect. Lancet 1993; 341: 134-138
41 Allaart CF, Aronson DC, Ruys T, Rosendaal FR, van Bockel JH, Bertina RM, Briet E. Hereditary protein S deficiency in young adults with arterial occlusive disease. Throm Haemost 1990; 64 (02) 206-210
42 Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-1508
43 Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation Factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men. N Eng1 J Med 1995; 332: 912-917
44 Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-3703
45 Mittleman MA, Siscovick DS. Physical exertion as a trigger of myocardial infarction and sudden cardiac death. Cardiol Clin 1996; 14: 263-270
46 Mead TW. Exercise and Haemostatic function. J Cardiovascular Risk 1995; 2 (04) 323-329